Clinical Trials
511
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (357 trials with phase data)• Click on a phase to view related trials
A Clinical Study of the Safety and Efficacy of Chemogenetics Therapy in the Treatment of Parkinson's Disease
- Conditions
- Parkinson Disease (PD)Gene TherapySafety and EfficacyClozapine
- Interventions
- Genetic: gene therapy
- First Posted Date
- 2025-07-25
- Last Posted Date
- 2025-07-25
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 6
- Registration Number
- NCT07085195
- Locations
- 🇨🇳
Department of neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC
- Conditions
- Colo-rectal CancerThird-line and Beyond TherapyTAS 102Bevacizumab
- Interventions
- Drug: Trifluridine/tipiracil (TAS-102) plus bevacizumab
- First Posted Date
- 2025-07-25
- Last Posted Date
- 2025-07-25
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT07085169
- Locations
- 🇨🇳
SanMing First Hospital, Sanming, China
🇨🇳Ruijin Hospital, Shanghai, China
A Prospective Observational Cohort Study on Longitudinal Monitoring of ctDNA MRD in Neoadjuvant Therapy for Pancreatic Cancer
- Conditions
- Pathologically Confirmed Pancreatic Cancer，High-risk Resectable, Borderline Resectable, or Locally Advanced Disease
- First Posted Date
- 2025-07-23
- Last Posted Date
- 2025-07-23
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 119
- Registration Number
- NCT07080021
- Locations
- 🇨🇳
Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China
🇨🇳Ruijin hospital, Shanghai, China
Golidocitinib With Azacitidine and Chidamide in Patients With Peripheral T-cell Lymphoma.
- Conditions
- Peripheral T-Cell Lymphoma, Not Classified
- Interventions
- Drug: golidocitinib with azacytidine and chidamide
- First Posted Date
- 2025-07-23
- Last Posted Date
- 2025-07-23
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT07081607
A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)
- First Posted Date
- 2025-07-18
- Last Posted Date
- 2025-07-18
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 56
- Registration Number
- NCT07072169
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai, Shanghai, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 102
- Next
News
Zambon Secures Chinese Approval for Intravenous Fluimucil Following Successful Phase 3 Trial
Zambon has received Chinese regulatory approval and launched the intravenous formulation of Fluimucil (N-acetylcysteine) for treating respiratory diseases with excessive mucus secretion.
CirCode Biomed's HM2002 Becomes World's First Circular RNA Drug to Receive FDA IND Clearance for Ischemic Heart Disease
CirCode Biomed announced FDA clearance for HM2002, marking the first circular RNA drug to receive IND approval for ischemic heart disease treatment.